In terms of CVD prevention, SGLT2 inhibitors and GLP1-RAs should be broadly considered for the treatment of diabetes in individuals with a moderate to high CV risk, with special consideration given to people with AF, HF and CKD. The gene discussed is GLP1R; the disease is chronic kidney disease.